In our previous multicenter retrospective clinical studies, we analysed CDA polymorphisms4,5 and CDA enzymatic activity5 in 126 advanced NSCLC patients treated with platinum/gemcitabine. This evidence concerns the gene CDA and non-small cell lung carcinoma.